Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial
Bhattacharyya S, Wilson R, Appiah-Kusi E, et al. JAMA Psychiatry. 2018;75(11):1107–1117. doi:10.1001/jamapsychiatry.2018.2309
This fMRI study of 33 individuals at high risk of developing psychosis showed that a single dose of cannabidiol normalised dysfunction in three areas of the brain (the striatum, medial temporal cortex and midbrain). Cannabidiol (CBD) is known to have antipsychotic effects in humans and these results may shed light on its mechanism of action. Although too early to say, CBD may have a role to play in the future management of psychosis.